Actively Recruiting

Phase Not Applicable
Age: 18Years - 90Years
All Genders
NCT07053618

Interventional Left Ventricular Assist System for PCI in CHIP Patients

Led by Suzhou Hengruihongyuan Medical Technology Co. LTD · Updated on 2025-08-26

286

Participants Needed

15

Research Sites

103 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Mechanical circulatory support (MCS) is a life-sustaining therapy first introduced in the 1950s. After six decades of development, it now serves as a critical bridge therapy for patients with acute cardiac events and end-stage heart failure. Percutaneous mechanical circulatory support (pMCS), a key MCS modality, has advanced rapidly in recent years. In China, pMCS adoption has accelerated significantly, evidenced by year-over-year growth in both specialized centers and clinical cases, alongside continuous technological refinement. Common pMCS devices include: Intra-Aortic Balloon Pump (IABP), Axial flow pump systems (e.g., Impella®), Extracorporeal Membrane Oxygenation (ECMO). However, no randomized study has compared Impella with VA-ECMO in CHIP patients. The aim of the study is to evaluate the effectiveness and safety of interventional left ventricular assist system (VADLINK) compared to the VA-ECMO in providing circulatory support for complicated and high-risk patient with indications for PCI.

CONDITIONS

Official Title

Interventional Left Ventricular Assist System for PCI in CHIP Patients

Who Can Participate

Age: 18Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged between 18 and 90 years
  • Requires coronary revascularization but is considered high-risk for or refuses coronary artery bypass grafting (CABG)
  • Left ventricular ejection fraction of 35% or less
  • Coronary imaging showing any of the following: unprotected left main artery disease (stenosis ≥ 50%), last remaining patent coronary artery, saphenous vein graft lesions, severe calcification or tortuosity, multivessel disease with chronic total occlusion, or three-vessel disease
  • Ability to give informed consent and complete follow-up
Not Eligible

You will not qualify if you...

  • Cardiogenic shock within the last 7 days
  • Recent STEMI or elevated CK-MB not normalized within 24 hours
  • Cardiac arrest with resuscitation within 24 hours
  • Left ventricular mural thrombus
  • History of aortic valve replacement surgery
  • Use of ECMO or percutaneous ventricular assist device within 7 days
  • Moderate to severe aortic valve disease
  • Heart defects such as septal defects or post-infarction ruptures
  • Severe right heart failure or tricuspid valve insufficiency
  • Aortic disease interfering with procedure, including Marfan syndrome or aneurysm
  • Severe peripheral arterial stenosis or occlusive disease
  • Moderate or severe anemia or abnormal coagulation
  • Known allergies or contraindications to heparin, contrast agents, or study medications
  • Active bleeding within 1 month
  • Stroke, transient ischemic attack, or permanent neurologic deficits within 1 month
  • Severe kidney or liver dysfunction
  • Infection or suspected infective endocarditis
  • Pregnant, breastfeeding, or planning pregnancy
  • Participation in another clinical trial
  • Other conditions deemed unsuitable by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

Beijing Tsinghua Changgung Hospital

Beijing, Beijing Municipality, China, 102218

Not Yet Recruiting

2

Zhongshan Hospital Affiliated to Xiamen University

Xiamen, Fujian, China, 361004

Not Yet Recruiting

3

The First Hospital of Lanzhou University

Lanzhou, Gansu, China, 730000

Not Yet Recruiting

4

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China, 510080

Not Yet Recruiting

5

Nanfang Hospital Southern Medical University

Guangzhou, Guangdong, China, 510515

Not Yet Recruiting

6

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China, 450052

Not Yet Recruiting

7

People's Hospital of Hunan Province

Changsha, Hunan, China, 410005

Not Yet Recruiting

8

Suzhou Municipal Hospital

Suzhou, Jiangsu, China, 215002

Not Yet Recruiting

9

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, China, 330006

Not Yet Recruiting

10

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China, 330006

Not Yet Recruiting

11

The People's Hospital of Liaoning Province

Shenyang, Liaining, China, 110015

Not Yet Recruiting

12

The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310009

Actively Recruiting

13

Zhejiang Hospital

Hangzhou, Zhejiang, China, 310013

Not Yet Recruiting

14

The First Affiliated Hospital of Ningbo University

Ningbo, Zhejiang, China, 315000

Not Yet Recruiting

15

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China, 325000

Not Yet Recruiting

Loading map...

Research Team

J

Jun Jiang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here